Leber Congenital Amaurosis Market Report 2026

The leber congenital amaurosis market size has grown strongly in recent years. It will grow from $1.06 billion in 2025 to $1.12 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to limited treatment options for inherited retinal disorders, increasing awareness of rare genetic eye diseases, advancements in retinal imaging technologies, growth in pediatric ophthalmology services, early research in gene replacement therapy.

The leber congenital amaurosis market size is expected to see strong growth in the next few years. It will grow to $1.39 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to rising investment in ophthalmic gene therapy research, expansion of precision medicine initiatives, increasing number of regulatory approvals for rare disease treatments, growing adoption of advanced genetic testing, expanding healthcare access for rare genetic disorders. Major trends in the forecast period include expansion of gene therapy approvals for inherited retinal diseases, rising focus on early genetic screening and diagnosis, growth in clinical trials for novel retinal regeneration therapies, increasing adoption of assistive vision technologies, advancements in retinal prosthesis and bionic eye solutions.

The rising prevalence of inherited retinal diseases is expected to drive the growth of the Leber congenital amaurosis (LCA) market. Inherited retinal diseases (IRDs) are genetic disorders that affect the retina, the light-sensitive tissue at the back of the eye responsible for vision. The increase in inherited retinal diseases is linked to improvements in genetic testing, greater awareness and diagnosis, and longer life expectancy. Advances in genetic testing have simplified the diagnosis of inherited retinal diseases, resulting in the identification of more cases. Leber congenital amaurosis contributes to the understanding of inherited retinal diseases by uncovering genetic mutations and disease mechanisms, which supports the development of targeted therapies and treatments. For example, in January 2025, according to the UK Parliament's House of Commons Library, around 25,000 people in the UK were affected by inherited retinal diseases in 2024, reflecting an annual increase of 2%. Thus, the rising prevalence of inherited retinal diseases is propelling the Leber congenital amaurosis market.

Major companies operating in the leber congenital amaurosis market are concentrating on developing innovative solutions, such as RNA-based therapies to enhance vision restoration and disease management. RNA-based treatments utilize RNA molecules to address diseases by targeting genetic mechanisms. These include mRNA vaccines, siRNA therapies, antisense oligonucleotides, and RNA aptamers. For example, in January 2025, Laboratoires Théa S.A.S., a France-based pharmaceutical company, launched Sepul Bio, a dedicated business unit focused on advancing RNA therapies for inherited retinal diseases, specifically targeting sepofarsen for leber congenital amaurosis 10 (LCA10) and ultevursen for USH2A-associated retinitis pigmentosa. Following the successful dosing of the first patient in the LUNA Phase 2b clinical trial for ultevursen, Sepul Bio is set to achieve significant progress in treating these rare genetic disorders.

In October 2024, Ocuphire Pharma Inc., a US-based biopharmaceutical company, acquired Opus Genetics Inc. for an undisclosed amount. Through this acquisition, Ocuphire Pharma intends to establish a leading clinical-stage biotechnology company dedicated to developing gene therapies for inherited retinal diseases (IRDs). Opus Genetics Inc. is a US-based gene therapy company specializing in treatments for inherited retinal diseases.

Major companies operating in the leber congenital amaurosis market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Invitae Corporation, Novelion Therapeutics Inc., Andelyn Biosciences Inc., CD Genomics Inc., Editas Medicine Inc., MeiraGTx Holdings plc, Sangamo Therapeutics Inc., LKC Technologies Inc., Aldeyra Therapeutics Inc., Asper Biogene OÜ, Allergan Inc., ProQR Therapeutics N.V., GenSight Biologics S.A., Ocugen Inc., Ophthotech Corporation, Atsena Therapeutics Inc., HuidaGene Therapeutics Co. Ltd.

North America was the largest region in the leber congenital amaurosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leber congenital amaurosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leber congenital amaurosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the leber congenital amaurosis market by increasing costs of imported gene therapy vectors, specialized ophthalmic devices, and advanced laboratory materials. Gene therapy and retinal prosthesis segments are most affected, particularly in north america and europe due to reliance on cross-border research and manufacturing. Higher treatment and procurement costs have influenced adoption rates in hospitals and specialized eye clinics. However, tariffs have supported localized manufacturing, regional research collaborations, and long-term strengthening of domestic ophthalmic biotechnology capabilities.

The leber congenital amaurosis market research report is one of a series of new reports that provides leber congenital amaurosis market statistics, including leber congenital amaurosis industry global market size, regional shares, competitors with a leber congenital amaurosis market share, detailed leber congenital amaurosis market segments, market trends and opportunities, and any further data you may need to thrive in the leber congenital amaurosis industry. This leber congenital amaurosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Leber congenital amaurosis (LCA) is a genetic eye disorder that causes severe vision loss or blindness from infancy due to mutations affecting the retina’s ability to detect light. It is characterized by poor visual response, involuntary eye movements (nystagmus), and extreme farsightedness resulting from disrupted photoreceptor function and progressive retinal degeneration.

The main treatment types for leber congenital amaurosis (LCA) include gene therapy, pharmaceutical drugs, retinal prostheses, assistive devices, and other treatments. Gene therapy is a medical technique that uses genetic material to treat or prevent diseases, such as LCA, by correcting defective genes. The age of onset for LCA is categorized into congenital LCA (from birth), early childhood LCA (1-5 years), and late-onset LCA (6 years and above). Pharmaceutical drugs for LCA are distributed through various channels, including direct tender and retail sales, and are used by end users such as hospitals, specialized eye clinics, ophthalmology research centers, and home care settings.

The leber congenital amaurosis (LCA) market consists of revenues earned by entities by providing services such as clinical trial services, healthcare and patient support services, vision rehabilitation services, and diagnostic testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The leber congenital amaurosis (LCA) market also includes sales of retinal implants, diagnostic testing kits, assistive devices, and gene therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.